1.Schwaber, MJ, Carmeli, Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA 2008;300:2911–2913.
2.Schwaber, MJ, Klarfeld-Lidji, S, Navon-Venezia, S, Schwartz, D, Leavitt, A, Carmeli, Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008;52:1028–1033.
3.Patel, G, Huprikar, S, Factor, SH, Jenkins, SG, Calfee, DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099–1106.
4.MacKenzie, FM, Forbes, KJ, Dorai-John, T, Amyes, SG, Gould, IM. Emergence of a carbapenem-resistant Klebsiella pneumoniae. Lancet 1997;350:783.
5.Bradford, PA, Urban, C, Mariano, N, Projan, SJ, Rahal, JJ, Bush, K. Imi-penem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC (3-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother 1997;41:563–569.
6.Deshpande, LM, Jones, RN, Fritsche, TR, Sader, HS. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Mi-crob Drug Resist 2006;12:223–230.
7.Srinivasan, A, Patel, JB. Klebsiella pneumoniae carbapenemase-producing organisms: an ounce of prevention really is worth a pound of cure. Infect Control Hosp Epidemiol 2008;29:1107–1109.
8.Bratu, S, Landman, D, Haag, R, et al.Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165:1430–1435.
9.Bratu, S, Mooty, M, Nichani, S, et al.Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005;49:3018–3020.
10.Leavitt, A, Navon-Venezia, S, Chmelnitsky, I, Schwaber, MJ, Carmeli, Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007;51:3026–3029.
11.Queenan, AM, Bush, K. Carbapenemases: the versatile /3-lactamases. Clin Microbiol Rev 2007;20:440–458.
12.Yigit, H, Queenan, AM, Anderson, GJ, et al.Novel carbapenem-hydro-lyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001;45:1151–1161.
13.Landman, D, Bratu, S, Kochar, S, et al.Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J Antimicrob Chemother 2007;60:78–82.
14.Rice, LB, Carias, LL, Hutton, RA, Rudin, SD, Endimiani, A, Bonomo, RA. The KQ element, a complex genetic region conferring transferable resistance to carbapenems, aminoglycosides, and fluoroquinolones in Klebsiella pneumoniae. Antimicrob Agents Chemother 2008;52:3427–3429.
15.Garner, JS, Emori, TG, Horan, TC, Hughes, JM. CDC definitions for nosocomial infections. In: Olmsted, RN, ed. APIC Infection Control and Applied Epidemiology: Principles and Practice. St Louis, MO: Mosby; 1996: A1–A20.
16.Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 19th information supplement. CLSI document. Wayne, PA: CLSI, 2009: M100–S19.
17.Moland, ES, Black, JA, Ourada, J, Reisbig, MD, Hanson, ND, Thomson, KS. Occurrence of newer β-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals. Antimicrob Agents Chemother 2002;46:3837–3842.
19.Goering, RV. Pulsed-field gel electrophoresis. In: Persing, DH, Tenover, FC, Versalovic, J, et al, eds. Microbiology: Diagnostic Principles and Practice. Washington, DC: ASM Press; 2004:185–196.
20.Siegel, JD, Jackson, M, Chiarello, L; The Health Care Infection Control Practice Advisory Committee. 2007 Guidelines for isolation precautions: preventing transmission of infectious agents in health care settings. Centers for Disease Control and Prevention Web site, http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html. Accessed July 27, 2009.
21.Larson, EL. APIC guideline for handwashing and hand antisepsis in health care settings. Am J Infect Control 1995;23:251–269.
22.Ressner, RA, Murray, CK, Griffith, ME, Rasnake, MS, Hospenthal, DR, Wolf, SE. Outcomes of bacteremia in burn patients involved in combat operations overseas. J Am Coll Surg 2008;206:439–444.
24.Aly, NY, Al-Mousa, HH, Al Asar el, SM. Nosocomial infections in a medical-surgical intensive care unit. Med Princ Pract 2008;17:373–377.
25.Kwak, YG, Choi, SH, Choo, EJ, et al.Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 2005;11:165–169.
26.Falagas, ME, Rafailidis, PI, Kofteridis, D, et al.Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007;60:1124–1130.
27.Hidron, AI, Edwards, JR, Patel, J, et al.NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996–1011.
28.Navon-Venezia, S, Leavitt, A, Schwaber, MJ, et al.First report on a hy-perepidemic clone of KAC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother 2009;53:818–820.
29.Rasheed, JK, Biddle, JW, Anderson, KF, et al.Detection of the Klebsiella pneumoniae carbapenemase type 2 carbapenem-hydrolyzing enzyme in clinical isolates of Citrobacter freundii and K oxytoca carrying a common plasmid. J Clin Microbiol 2008;46:2066–2069.
30.Wolter, DJ, Kurpiel, PM, Woodford, N, Palepou, MF, Goering, RV, Hanson, ND. Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. Antimicrob Agents Chemother 2009;53:557–562.
31.Wolter, DJ, Khalaf, N, Robledo, IE, et al.Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican medical center hospitals: dissemination of KPC and IMP-18 β-lactamases. Antimicrob Agents Chemother 2009;53(4):1660–1664.
32.Allman, RM, Goode, PS, Burst, N, Bartolucci, AA, Thomas, DR. Pressure ulcers, hospital complications, and disease severity: impact on hospital costs and length of stay. Adv Wound Care 1999;12:22–30.
33.Hung, EW, Darouiche, RO, Trautner, BW. Proteus bacteriuria is associated with significant morbidity in spinal cord injury. Spinal Cord 2007;45:616–620.
34.Hussain, R, Cevallos, ME, Darouiche, RO, Trautner, BW. Gram-negative intravascular catheter-related bacteremia in patients with spinal cord injury. Arch Phys Med Rehabil 2008;89:339–342.
35.Lodise, TP Jr, McKinnon, PS, Rybak, M. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect Control Hosp Epidemiol 2003;24:655–661.
36.Roghmann, MC, Siddiqui, A, Plaisance, K, Standiford, H. MRSA colonization and the risk of MRSA bacteraemia in hospitalized patients with chronic ulcers. J Hosp Infect 2001;47:98–103.
37.Kanafani, ZA, Mehio-Sibai, A, Araj, GF, Kanaan, M, Kanj, SS. Epidemiology and risk factors for extended-spectrum β-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control 2005;33:326–332.
38.Lin, MF, Huang, ML, Lai, SH. Risk factors in the acquisition of extended-spectrum (3-lactamase Klebsiella pneumoniae, a case-control study in a district teaching hospital in Taiwan. J Hosp Infect 2003;53:39–45.
39.Eveillard, M, Quenon, JL, Rufat, P, Mangeol, A, Fauvelle, F. Association between hospital-acquired infections and patients' transfers. Infect Control Hosp Epidemiol 2001;22:693–696.
40. Centers for Disease Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing En-terobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009;58(10):256–260.